Ceribell Inc. (NASDAQ: CBLL) Chief Revenue Officer Joseph S. Manni sold 1,361 shares of common stock on August 21 for a total of $32,691, according to a regulatory filing. The transaction was executed to cover tax withholding obligations tied to the vesting of restricted stock units.
Manni retained 55,956 shares of Ceribell common stock, including 1,026 shares acquired under the company’s Employee Stock Purchase Plan on July 31. The shares were sold at $24.02 each, with Ceribell’s stock trading near its 52-week high of $25.33—a level reflecting a 109% return over the past 12 months.
The sale follows strong financial performance in the second quarter of fiscal 2026. Revenue reached $28.1 million, a 33% year-over-year increase, accelerating from the 29% growth reported in the first quarter. Gross profit margins stood at 88.9%, while the company maintained a net loss of $0.51 per share, wider than the $0.36 loss forecast by analysts.
Ceribell added 32 new accounts during the quarter, slightly below Canaccord’s estimate of 36, supported by robust same-store utilization. Growth drivers included the seizure-detection business, delirium monitoring, and pediatric care products.
Analysts at Canaccord raised their price target to $26 from $25, maintaining a Buy rating. BTIG also upgraded its target to $30 from $28, citing the company’s leadership in point-of-care rapid EEG technology and growth outlook.
